Hematopoietic stem cell transplantation: A primer for the primary care physician

CMAJ. Canadian Medical Association Journal

Volumn 170, Issue 10, 2004, Pages 1569-1577

  Léger, Chantal S ^a,d,e   Nevill, Thomas J ^b,c,d  

^a ST PAUL S HOSPITAL   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHICKENPOX VACCINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPHTHERIA TETANUS TOXOID; GANCICLOVIR; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; METHOTREXATE; PENTAMIDINE; PNEUMOCOCCUS POLYSACCHARIDE; THYMOCYTE ANTIBODY;

ACNE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AVASCULAR NECROSIS; BACTERIAL INFECTION; BLEEDING; CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; ENDOCRINE DISEASE; FERTILITY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HIRSUTISM; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LENGTH OF STAY; LUNG INFECTION; LYMPHOMA; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MYOPATHY; NEUTROPENIA; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PANCYTOPENIA; PHYSICIAN; PREMEDICATION; RECIPIENT; REVIEW; RISK FACTOR; SKIN DISEASE; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS INFECTION; WHOLE BODY RADIATION;

EID: 2542473353     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1011625     Document Type: Review

References (53)

1. Santos GW. Bone marrow transplantation. In: Stollerman GH, editor. Advances in internal medicine. Chicago: Year Book Publishers; 1975. p. 157-82.
2. Lorenz E, Uphoff DE, Reid TR, Shelton E. Modification of acute irradiation injury in mice and guinea pigs by bone marrow injection. Radiology 1951;58:863-77.
3. Cohen JA, Vos O, van Bekkum DW. The present status of radiation protection by chemical and biological agents in mammals. In: de Hevesy GC, Forssberg AG, Abbott JD, editors. Advances in radiobiology. Edinburgh: Oliver and Boyd; 1957. p. 134-44.
4. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966-67;62:21-78.
5. Bearman SI, Mori M, Beatty PG, Meyer WG, Buckner CD, Petersen FB, et al. Comparison of morbidity and mortality after marrow transplantation from HLA-genotypically identical siblings and HLA-phenotypically identical unrelated donors. Bone Marrow Transplant 1994;13(1):31-5.
6. Oudshoorn M, van Leeuwen A, vd Zanden HG, van Rood JJ. Bone Marrow Donors Worldwide: a successful exercise in international cooperation. Bone Marrow Transplant 1994;14(1):3-8.
7. Bensinger WI, Price TH, Dale DC, Appelbaum FR, Clift R, Lilleby K, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993;81(7):1883-8.
8. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-81.
9. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K, et al; Canadian Bone Marrow Transplant Group. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002;100(5):1525-31.
10. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335(3):157-66.
11. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997;337(6):373-81.
12. Moller G, editor. Lymphocyte homing. Immunol Rev 1989;108:5-161.
13. Fefer A, Einstein AB, Thomas ED, Buckner CD, Clift RA, Glucksberg H, et al. Bone marrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med 1974;290(25):1389-93.
14. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994;84(6):2036-43.
15. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6(10):1562-8.
16. Centers for Disease Control and Prevention; Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000;6:659-734.
17. Andrykowski MA. Psychosocial factors in bone marrow transplantation: a review and recommendations for research. Bone Marrow Transplant 1994;13:357-75.
18. Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002;29:545-52.
19. Lum LG. Kinetics of immune reconstitution after human marrow transplantation. Blood 1987;69:369-80.
20. Korngold R, Sprent J. T cell subsets in graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, editors. Graft-versus-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker; 1996. p. 31-50.
21. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15(6):825-8.
22. Chao NJ, Deeg HF. In vivo prevention and treatment of graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, editors. Graft-versus-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker; 1996. p. 639-66.
23. Martin PJ, Hansen JA, Torok-Storb B, Durnam D, Przepiorka D, O'Quigley J, et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988;3:445-56.
24. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555-62.
25. Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Hogge DE, Sutherland HG, et al. Stem cell transplant-related mortality (TRM) 1985-96: the Vancouver experience [abstract]. Blood 1997;90(Suppl 1):373b.
26. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332(4):217-23.
27. Schwartzberg LS, Birch R, Hazelton B, Tauer KW, Lee P Jr, Altemose R, et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992;1(3):317-27.
28. Leger CS, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsch L. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant 2000;6(2A):204-10.
29. Weaver CH, Schwartzberg L, Zhen B, Mangum M, Leff R, Tauer K, et al. High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: results of outpatient treatment in community cancer centers. Bone Marrow Transplant 1997;20:753-60.
30. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69(2):204-17.
31. Roy V, Ochs L, Weisdorf D. Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Leuk Lymphoma 1997;26:1-15.
32. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, et al. Alternating-day cyclosporine and prednisone for the treatment of high-risk chronic graft-v-host disease. Blood 1988;72(2):555-61.
33. Storek J, Joseph A, Espino G, Dawson MA, Douek DC, Sullivan KM, et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation [published erratum appears in Blood 2002;99(5):1511]. Blood 2001;98(12):3505-12.
34. Atkinson K, Farewell V, Storb R, Tsoi MS, Sullivan KM, Witherspoon RP, et al. Analysis of late infections after human marrow transplantation: role of non-specific suppressor cells in patients with chronic graft-versus-host disease. Blood 1982;60(3):714-20.
35. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors, and complications. Bone Marrow Transplant 1994;13(3):277-83.
36. Ormrod D, Goa K. Valacyclovir: a review of its use in the management of herpes zoster. Drugs 2000;59:1317-40.
37. Meyers JD, Fluornoy N, Thomas ED. Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. J Infect Dis 1980;142(6):816-24.
38. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1992;10(3):267-72.
39. Pauksen K, Hammarstrom V, Ljungman P, Sjolin J, Oberg G, Lonnerholm G, et al. Immunity to poliovirus and immunization with inactivated poliovirus vaccine after autologous bone marrow transplantation. Clin Infect Dis 1994;18(4):547-52.
40. Ljungman P, Wiklund-Hammarsten M, Duraj V, Hammarstrom L, Lonnqvist B, Paulin T, et al. Responses to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990;162:496-500.
41. Sanders JE, Buckner CD, Leonard JM, Sullivan KM, Witherspoon RP, Deeg HJ, et al. Late effects on gonadal function of cyclophosphamide, total body irradiation, and marrow transplantation. Transplantation 1983;36(3):252-5.
42. Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996;87(7):3045-52.
43. Anserini P, Chiodi S, Spinelli S, Costa M, Conte N, Copello F, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counseling. Bone Marrow Transplant 2002;30(4):447-51.
44. Grigg AP, McLachlan R, Zaja J, Szer J. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant 2000;26(10):1089-95.
45. Schimmer AD, Quatermain M, Imrie K, Ali V, McCrae J, Stewart AK, et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol 1998;16(7):2359-63.
46. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997;336(13):897-904.
47. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999;341(1):14-21.
48. Forrest DL, Nevill TJ, Naiman SC, Le A, Brockington DA, Barnett MJ, et al. Second malignancy following high-dose therapy and autolgous stem cell transplantation: incidence and risk factor analysis. Bone Marrow Transplant 2003;32(9):915-23.
49. Lavoie J, Connors J, Smith C, Voss NG, Reece DE, Philips GL. Ten-year follow-up of the first 100 patients having received high-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin's disease in Vancouver: long-term complications and causes of death [abstract]. Blood 2003;102:116.
50. Chao NJ, Tierney DK, Bloom JR, Long GD, Barr TA, Stallbaum BA, et al. Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood 1992;80(3):825-30.
51. Andrykowski MA, Henslee PJ, Farrall MG. Physical and psychological functioning of adult survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 1989;4:75-81.
52. Long GD, Laughlin M, Madan B, Kurtzberg J, Gasparetto C, Morris A, et al. Unrelated cord blood transplantation in adult patients. Biol Blood Marrow Transplant 2003;9(12):772-80.
53. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89(12):4531-6.